You just read:

Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 10, 2018, 09:00 EST